Comments
Drug firm Alembic Pharmaceuticals today reported a 35.69 per cent rise in its consolidated net profit to Rs 90.47 crore for the quarter ended June 30 on account of robust sales.
The company had posted a net profit after taxes, non-controlling interests and share of profit of associates and joint ventures of Rs 66.67 crore for the same period of the previous fiscal, Alembic Pharmaceuticals said in a BSE filing.
Consolidated revenue from operations of the company stood at Rs 862.53 crore for the quarter under consideration. It was Rs 648.19 crore for the corresponding period a year ago.
Alembic Pharmaceuticals MD, Pranav Amin, said: “The robust performance in the quarter is attributed to growth across territories. This was led by the India formulation business, which was impacted by GST transition last year.”
Shares of Alembic Pharmaceuticals were today trading 2.36 per cent higher at Rs 570.60 per scrip on the BSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.